Reactivity of valganciclovir in aqueous solution

Drug Development and Industrial Pharmacy

Volumn 31, Issue 9, 2005, Pages 879-884

  Stefanidis, Dimitrios ^a   Brandl, Michael ^a  

^a Pharmaceutics Department   (United States)

Author keywords

Ganciclovir; Hydrolysis; Isomerization; Prodrug; Valganciclovir

Indexed keywords

VALGANCICLOVIR;

AQUEOUS SOLUTION; ARTICLE; CATALYSIS; DRUG DEGRADATION; DRUG FORMULATION; DRUG HYDROLYSIS; DRUG STABILITY; DRUG STRUCTURE; HALF LIFE TIME; ISOMERIZATION; PH;

BUFFERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; GANCICLOVIR; HALF-LIFE; HYDROGEN-ION CONCENTRATION; HYDROLYSIS; KINETICS; SOLUTIONS; STEREOISOMERISM; VALINE;

EID: 27544464267     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.1080/03639040500271951     Document Type: Article

References (5)

1. Curran, M., & Noble, S. (2001). Valganciclovir. Drugs, 61(8), 1145-1150.
2. Jung, D., & Dorr, A. (1999). Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects. Journal of Clinical Pharmacology, 59(8), 800-804.
3. Nestor, J. J., Womble, S. W., & Maag, H. (1996). 2-(2-Amino-1,6- dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol L-monovaline ester (ganciclovir valine ester) as an antiviral with improved oral absorption. Eur. Pat. Appl. (1996), 25 pp. Application: EP 95-111319.
4. Sugawara, M., Huang, W., Fei, Y.-J., Leibach, F. H., Ganapathy, V., & Ganapathy, M. E. (2000). Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2. Journal of Pharmaceutical Sciences, 89(6), 781-789.
5. Valcyte TM. (2004). In Physician's Desk Reference (p. 2970). Montvale, NJ: Thomson Healthcare.